Search

Displaying results 4101 - 4110 of 10000 in total
  1. Drug

    Pumactant

    go.drugbank.com/drugs/DB04955
    Experimental

    Pumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. … It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).

  2. Drug

    Fenoprofen

    go.drugbank.com/drugs/DB00573
    Approved

    An anti-inflammatory analgesic and antipyretic highly bound to plasma proteins. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.

  3. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  4. Drug

    Piroximone

    go.drugbank.com/drugs/DB19750
    Experimental

    Piroximone is a small molecule drug. Piroximone has a monoisotopic molecular weight of 217.09 Da.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Mecrylate

    go.drugbank.com/drugs/DB21343
    Experimental

    Mecrylate is a small molecule drug. Mecrylate has a monoisotopic molecular weight of 111.03 Da.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Rupintrivir

    go.drugbank.com/drugs/DB05102
    Experimental

    Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus. … Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections.

  7. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  8. Drug

    Lunacalcipol

    go.drugbank.com/drugs/DB05024
    Investigational

    secretion which may be involved in the etiology of psoriasis. … Preclinical studies have shown that CTA018 inhibits the proliferation of rapidly dividing cells such as human epidermal keratinocytes (skin cells) and is also effective in inhibiting pro-inflammatory cytokine

  9. Drug

    Torcetrapib

    go.drugbank.com/drugs/DB06281
    Investigational

    Torcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination

  10. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure